4-Methylmorpholine → 3-tert-Butyl-N-(3-{6-[1-(4-methoxybenzyl)-1H-pyrazol-4-yl]-1H-imidazo[1,2-b]pyrazol-1-yl}-4-methylphenyl)-5-(4-methylpiperazin-1-yl)benzamide
반응식
F[C:2](F)(F)[C:3]([OH:5])=O.COC1C=CC([CH2:14][N:15]2[CH:19]=[C:18]([C:20]3[CH:21]=[C:22]4[N:27]([C:28]5[CH:29]=[C:30]([CH:32]=[CH:33][C:34]=5[CH3:35])[NH2:31])[CH:26]=[CH:25][N:23]4[N:24]=3)[CH:17]=[N:16]2)=CC=1.F[C:39](F)(F)C(O)=O.[C:45]([C:49]1[CH:50]=[C:51]([CH:55]=[C:56]([N:58]2[CH2:63][CH2:62][N:61]([CH3:64])[CH2:60][CH2:59]2)[CH:57]=1)[C:52](O)=[O:53])([CH3:48])([CH3:47])[CH3:46].CN(C(ON1N=N[C:75]2[CH:76]=[CH:77]C=N[C:74]1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.CN1CCOCC1.[OH-].[Na+]>CN(C=O)C>[C:45]([C:49]1[CH:50]=[C:51]([CH:55]=[C:56]([N:58]2[CH2:63][CH2:62][N:61]([CH3:64])[CH2:60][CH2:59]2)[CH:57]=1)[C:52]([NH:31][C:30]1[CH:32]=[CH:33][C:34]([CH3:35])=[C:28]([N:27]2[C:22]3[N:23]([N:24]=[C:20]([C:18]4[CH:17]=[N:16][N:15]([CH2:14][C:75]5[CH:74]=[CH:2][C:3]([O:5][CH3:39])=[CH:77][CH:76]=5)[CH:19]=4)[CH:21]=3)[CH:25]=[CH:26]2)[CH:29]=1)=[O:53])([CH3:48])([CH3:47])[CH3:46]참가 물질
7
반응물 5
생성물 1
시약·촉매·용매 1
실험 절차
65 mg (0.13 mmol) of the compound of Example 8A, 50 mg (0.13 mmol) of the compound of Example 21A and 58 mg (0.15 mmol) of HATU were dissolved in 0.73 ml of DMF, 0.07 ml (0.63 mmol) of 4-methylmorpholine was added and the mixture was stirred at RT for 16 h. 10 ml of 0.1 M aqueous sodium hydroxide solution were then added, and the mixture was stirred at RT for another 10 min. The precipitate formed was filtered off, washed with water and dried under high vacuum. This gave 70 mg (76% pure, 64% of theory) of the title compound.
후처리
- stirringthe mixture was stirred at RT for another 10 min
- customThe precipitate formed
- filtrationwas filtered off
- washwashed with water
- customdried under high vacuum
출처 및 근거
- ORD 기록
- ord-ce50c68d8223493abb2f064faca2495d
- 출처 데이터셋
- uspto-grants-2016_07
- 특허 번호
- US09394309B2
반응 노트
불러오는 중…